Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Diagn Microbiol Infect Dis ; 97(2): 115028, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32278620

ABSTRACT

The aim of this study was to evaluate the clinical value of partial 16S/18S rRNA gene sequencing with the commercial kit Micro-Dx™ used with the SelectNA™plus instrument on culture-negative samples. A retrospective study of microbiological and clinical data from a 2.5-year period was performed. Assessment of the clinical relevance of the 16S/18S rRNA gene sequencing results was based on evaluation of the results in the clinical context and changes in antimicrobial therapy. Included were 529 samples from 223 patients, representing 251 episodes. In 191 samples (36.1%), bacterial/fungal DNA was detected. Positive results were judged clinically relevant in 79 (31.5%) episodes. Antimicrobial treatment was adjusted according to the 16S/18S rRNA gene sequence analysis result in 42 (16.7%) episodes. The results from 16S/18S rRNA gene sequence analysis were highly clinically relevant. These findings support the use of this analysis in a routine setting.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteria/isolation & purification , Fungi/genetics , Molecular Diagnostic Techniques/standards , Polymerase Chain Reaction , Adolescent , Adult , Aged , Aged, 80 and over , Bacteria/growth & development , Bacterial Infections/diagnosis , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Child , Child, Preschool , Colony Count, Microbial/statistics & numerical data , DNA, Bacterial/genetics , DNA, Fungal/genetics , Female , Fungi/growth & development , Humans , Infant , Male , Middle Aged , Molecular Diagnostic Techniques/instrumentation , Molecular Diagnostic Techniques/methods , RNA, Ribosomal, 16S/genetics , Reagent Kits, Diagnostic/standards , Retrospective Studies , Sequence Analysis, DNA , Young Adult
2.
Clin Microbiol Infect ; 26(2): 227-234, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31238116

ABSTRACT

OBJECTIVES: The role of Pseudomonas aeruginosa in the long-term prognosis of chronic obstructive pulmonary disease (COPD) is unknown. The purpose of this study was to determine whether P. aeruginosa is associated with increased risk of exacerbations or death in patients with COPD. METHODS: This is a multiregional epidemiological study based on complete data on COPD outpatients between 1 January 2010 and 31 October 2017 and corresponding microbiology and national register data. Time-dependent Cox proportional hazards models and propensity matching was used to estimate hospitalization-demanding exacerbations and death after 2 years, separately and in combination. RESULTS: A total of 22 053 COPD outpatients were followed for a median of 1082 days (interquartile-range: 427-1862). P. aeruginosa was present in 905 (4.1%) patients. During 730 days of follow-up, P. aeruginosa strongly and independently predicted an increased risk of hospitalization for exacerbation or all-cause death (HR 2.8, 95%CI 2.2-3.6; p <0.0001) and all-cause death (HR 2.7, 95%CI 2.3-3.4; p <0.0001) in analyses adjusted for known and suspected confounders. The signal remained unchanged in unadjusted analyses as well as propensity-matched subgroup analyses. Among patients 'ever colonized' with P. aeruginosa, the incidence of hospital-demanding exacerbations doubled after the time of the first colonization. CONCLUSIONS: COPD patients in whom P. aeruginosa can be cultured from the airways had a markedly increased risk of exacerbations and death. It is still not clear whether this risk can be reduced by offering patients targeted antipseudomonal antibiotics. A randomized trial is currently recruiting patients to clarify this (ClinicalTrials.gov: NCT03262142).


Subject(s)
Pseudomonas Infections/mortality , Pulmonary Disease, Chronic Obstructive/microbiology , Pulmonary Disease, Chronic Obstructive/mortality , Aged , Disease Progression , Female , Follow-Up Studies , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Outpatients/statistics & numerical data , Proportional Hazards Models , Pseudomonas Infections/epidemiology , Pseudomonas aeruginosa , Randomized Controlled Trials as Topic , Respiratory System/microbiology , Risk Factors , Symptom Flare Up
3.
Br J Surg ; 107(3): 310-315, 2020 02.
Article in English | MEDLINE | ID: mdl-31755092

ABSTRACT

BACKGROUND: Systemic inflammation following curative surgery for colorectal cancer may be associated with increased risk of recurrence. [Correction added on 29 November 2019, after first online publication: text amended for accuracy.] This study investigated whether a clinically suspected infection, for which blood cultures were sent within 30 days after surgery for colorectal cancer, was associated with long-term oncological outcomes. METHODS: This register-based national cohort study included all Danish residents undergoing surgery with curative intent for colorectal cancer between January 2003 and December 2013. Patients who developed recurrence or died within 180 days after surgery were not included. Associations between blood cultures taken within 30 days after primary surgery and overall survival, disease-free survival and recurrence-free survival were analysed using Cox regression models adjusted for relevant clinical confounders, including demographic data, cancer stage, co-morbidity, blood transfusion, postoperative complications and adjuvant chemotherapy. RESULTS: The study included 21 349 patients, of whom 3390 (15·9 per cent) had blood cultures taken within 30 days after surgery. Median follow-up was 5·6 years. Patients who had blood cultures taken had an increased risk of all-cause mortality (hazard ratio (HR) 1·27, 95 per cent c.i. 1·20 to 1·35; P < 0·001), poorer disease-free survival (HR 1·22, 1·16 to 1·29; P < 0·001) and higher risk of recurrence (HR 1·15, 1·07 to 1·23; P < 0·001) than patients who did not have blood cultures taken. CONCLUSION: A clinically suspected infection requiring blood cultures within 30 days of surgery for colorectal cancer was associated with poorer oncological outcomes.


ANTECEDENTES: La inflamación sistémica en el cáncer colorrectal puede asociarse con un aumento del riesgo de recidiva. En este estudio se investigó si la sospecha clínica de infección, en la que se obtuvieron cultivos de sangre periférica durante los primeros 30 días de la cirugía por cáncer colorrectal, se asociaba con los resultados oncológicos a largo plazo. MÉTODOS: Se trata de un estudio de cohortes de un registro de una base de datos nacional, que incluyía todos los sujetos residentes en Dinamarca sometidos a cirugía por cáncer colorrectal con intención curativa desde enero de 2003 a diciembre de 2013. Los pacientes con recidiva o que fallecieron durante los primeros 180 días después de la cirugía fueron excluidos. Se estimaron las asociaciones entre los cultivos de sangre periférica efectuados en los primeros 30 días tras la cirugía primaria y la supervivencia global, supervivencia libre de enfermedad y supervivencia libre de recidiva mediante modelos de regresión de Cox, ajustados por variables clínicas confusoras relevantes (incluyendo datos demográficos, estadio del cáncer, comorbilidad, transfusión de sangre, complicaciones postoperatorias y quimioterapia adyuvante). RESULTADOS: El estudio incluyó 21.349 pacientes, de los cuales en 3.390 (16%) se habían obtenido cultivos de sangre periférica durante los primeros 30 días tras la cirugía. La mediana de seguimiento fue de 5,6 años. Los pacientes en los que se había obtenido cultivos de sangre periférica presentaron un riesgo aumentado de mortalidad por cualquier causa (cociente de riesgos instantáneos, hazard ratio, HR 1,27, i.c. del 95% 1,20-1,35; P < 0.0001), peor supervivencia libre de enfermedad (HR 1,22, i.c. del 95% 1,16-1,29; P < 0,0001) y mayor riesgo de recidiva (HR 1,15, i.c. del 95% 1,07-1,23; P < 0,0001) que los pacientes en los que no se habían obtenido cultivos. CONCLUSIÓN: La presencia de una infección sospechada clínicamente para la cual se requiere obtener cultivos de sangre periférica en los primeros 30 días tras cirugía por cancer colorrectal se asoció con peores resultados oncológicos.


Subject(s)
Colectomy , Colorectal Neoplasms/surgery , Postoperative Complications/blood , Registries , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Blood Culture , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/mortality , Denmark/epidemiology , Disease-Free Survival , Female , Follow-Up Studies , Humans , Male , Middle Aged , Postoperative Complications/diagnosis , Postoperative Complications/mortality , Retrospective Studies , Risk Factors , Survival Rate/trends , Time Factors
4.
Clin Microbiol Infect ; 24(2): 118-124, 2018 Feb.
Article in English | MEDLINE | ID: mdl-28887186

ABSTRACT

BACKGROUND: Lyme borreliosis (LB) is a tick-borne infection caused by Borrelia burgdorferi sensu lato. The most frequent clinical manifestations are erythema migrans and Lyme neuroborreliosis. Currently, a large volume of diagnostic testing for LB is reported, whereas the incidence of clinically relevant disease manifestations is low. This indicates overuse of diagnostic testing for LB with implications for patient care and cost-effective health management. AIM: The recommendations provided in this review are intended to support both the clinical diagnosis and initiatives for a more rational use of laboratory testing in patients with clinically suspected LB. SOURCES: This is a narrative review combining various aspects of the clinical and laboratory diagnosis with an educational purpose. The literature search was based on existing systematic reviews, national and international guidelines and supplemented with specific citations. IMPLICATIONS: The main recommendations according to current European case definitions for LB are as follows. Typical erythema migrans should be diagnosed clinically and does not require laboratory testing. The diagnosis of Lyme neuroborreliosis requires laboratory investigation of the spinal fluid including intrathecal antibody production, and the remaining disease manifestations require testing for serum antibodies to B. burgdorferi. Testing individuals with non-specific subjective symptoms is not recommended, because of a low positive predictive value.


Subject(s)
Clinical Laboratory Techniques , Lyme Disease/diagnosis , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Borrelia burgdorferi/immunology , Clinical Laboratory Techniques/standards , Humans , Immunoglobulin M/blood , Immunoglobulin M/immunology
6.
Pharmacogenomics J ; 18(3): 494-500, 2018 05 22.
Article in English | MEDLINE | ID: mdl-28696418

ABSTRACT

Biological agents including anti-tumor necrosis factor (anti-TNF; adalimumab, infliximab, etanercept) and anti-interleukin-12/13 (IL12/23; ustekinumab) are essential for treatment of patients with severe psoriasis. However, a significant proportion of the patients do not respond to a specific treatment. Pharmacogenetics might be a way to predict treatment response. Using a candidate gene approach, 62 mainly functional single-nucleotide polymorphisms (SNPs) in 44 different genes were evaluated in 478 Danish patients with psoriasis undergoing 376 series of anti-TNF treatment and 230 series of ustekinumab treatment. Associations between genetic variants and treatment outcomes (drug survival and Psoriasis Area Severity Index reduction) were assessed using logistic regression analyses (crude and adjusted for gender, age, psoriatic arthritis and previous treatment). After correction for multiple testing controlling the false discovery rate, six SNPs (IL1B (rs1143623, rs1143627), LY96 (rs11465996), TLR2 (rs11938228, rs4696480) and TLR9 (rs352139)) were associated with response to anti-TNF treatment and 4 SNPs (IL1B (rs1143623, rs1143627), TIRAP (rs8177374) and TLR5 (rs5744174)) were associated with response to ustekinumab treatment (q<0.20). The results suggest that genetic variants related to increased IL-1ß levels may be unfavorable when treating psoriasis with either anti-TNF or ustekinumab, whereas genetic variants related to high interferon-γ levels may be favorable when treating psoriasis with ustekinumab.


Subject(s)
Pharmacogenetics/methods , Psoriasis/drug therapy , Psoriasis/genetics , Adalimumab/administration & dosage , Adalimumab/adverse effects , Adult , Denmark , Etanercept/administration & dosage , Etanercept/adverse effects , Female , Humans , Infliximab/administration & dosage , Infliximab/adverse effects , Interleukin-1beta/genetics , Lymphocyte Antigen 96/genetics , Male , Membrane Glycoproteins/genetics , Middle Aged , Polymorphism, Single Nucleotide , Psoriasis/epidemiology , Psoriasis/pathology , Receptors, Interleukin-1/genetics , Toll-Like Receptor 2/genetics , Toll-Like Receptor 9/genetics , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Ustekinumab/administration & dosage , Ustekinumab/adverse effects
7.
J Parasitol Res ; 2017: 6205257, 2017.
Article in English | MEDLINE | ID: mdl-29181192

ABSTRACT

Microscopy of stool samples is a labour-intensive and inaccurate technique for detection of intestinal parasites causing diarrhoea and replacement by PCR is attractive. Almost all cases of diarrhoea induced by parasites over a nine-year period in our laboratory were due to Giardia lamblia, Cryptosporidium species, or Entamoeba histolytica detected by microscopy. We evaluated and selected in-house singleplex real-time PCR (RT-PCR) assays for these pathogens in 99 stool samples from patients suspected of having intestinal parasitosis tested by microscopy. The strategy included a genus-specific PCR assay for C. parvum and C. hominis, with subsequent identification by a PCR that distinguishes between the two species. G. lamblia was detected in five and C. parvum in one out of 68 microscopy-negative samples. The performance of the in-house RT-PCR assays was compared to three commercially available multiplex test (MT-PCR) kit systems in 81 stool samples, collected in 28 microscopy-positive and 27 microscopy-negative samples from individuals suspected of intestinal parasitosis and in 26 samples from individuals without suspicion of parasitic infection. The in-house assays detected parasites in more samples from patients suspected of having parasitosis than did any of the kits. We conclude that commercial kits are targeting relevant parasites, but their performance may vary.

8.
BMC Infect Dis ; 16: 140, 2016 Mar 25.
Article in English | MEDLINE | ID: mdl-27013465

ABSTRACT

BACKGROUND: Interpretation of serological assays in Lyme borreliosis requires an understanding of the clinical indications and the limitations of the currently available tests. We therefore systematically reviewed the accuracy of serological tests for the diagnosis of Lyme borreliosis in Europe. METHODS: We searched EMBASE en MEDLINE and contacted experts. Studies evaluating the diagnostic accuracy of serological assays for Lyme borreliosis in Europe were eligible. Study selection and data-extraction were done by two authors independently. We assessed study quality using the QUADAS-2 checklist. We used a hierarchical summary ROC meta-regression method for the meta-analyses. Potential sources of heterogeneity were test-type, commercial or in-house, Ig-type, antigen type and study quality. These were added as covariates to the model, to assess their effect on test accuracy. RESULTS: Seventy-eight studies evaluating an Enzyme-Linked ImmunoSorbent assay (ELISA) or an immunoblot assay against a reference standard of clinical criteria were included. None of the studies had low risk of bias for all QUADAS-2 domains. Sensitivity was highly heterogeneous, with summary estimates: erythema migrans 50% (95% CI 40% to 61%); neuroborreliosis 77% (95% CI 67% to 85%); acrodermatitis chronica atrophicans 97% (95% CI 94% to 99%); unspecified Lyme borreliosis 73% (95% CI 53% to 87%). Specificity was around 95% in studies with healthy controls, but around 80% in cross-sectional studies. Two-tiered algorithms or antibody indices did not outperform single test approaches. CONCLUSIONS: The observed heterogeneity and risk of bias complicate the extrapolation of our results to clinical practice. The usefulness of the serological tests for Lyme disease depends on the pre-test probability and subsequent predictive values in the setting where the tests are being used. Future diagnostic accuracy studies should be prospectively planned cross-sectional studies, done in settings where the test will be used in practice.


Subject(s)
Lyme Disease/diagnosis , Area Under Curve , Databases, Factual , Enzyme-Linked Immunosorbent Assay , Europe/epidemiology , Humans , Lyme Disease/epidemiology , ROC Curve , Sensitivity and Specificity , Serologic Tests
9.
Euro Surveill ; 20(28)2015 Jul 16.
Article in English | MEDLINE | ID: mdl-26212143

ABSTRACT

Our aim was to evaluate the results of automated surveillance of Lyme neuroborreliosis (LNB) in Denmark using the national microbiology database (MiBa), and to describe the epidemiology of laboratory-confirmed LNB at a national level. MiBa-based surveillance includes electronic transfer of laboratory results, in contrast to the statutory surveillance based on manually processed notifications. Antibody index (AI) testing is the recommend laboratory test to support the diagnosis of LNB in Denmark. In the period from 2010 to 2012, 217 clinical cases of LNB were notified to the statutory surveillance system, while 533 cases were reported AI positive by the MiBa system. Thirty-five unconfirmed cases (29 AI-negative and 6 not tested) were notified, but not captured by MiBa. Using MiBa, the number of reported cases was increased almost 2.5 times. Furthermore, the reporting was timelier (median lag time: 6 vs 58 days). Average annual incidence of AI-confirmed LNB in Denmark was 3.2/100,000 population and incidences stratified by municipality ranged from none to above 10/100,000. This is the first study reporting nationwide incidence of LNB using objective laboratory criteria. Laboratory-based surveillance with electronic data-transfer was more accurate, complete and timely compared to the surveillance based on manually processed notifications. We propose using AI test results for LNB surveillance instead of clinical reporting.


Subject(s)
Borrelia/isolation & purification , Lyme Disease/diagnosis , Lyme Neuroborreliosis/diagnosis , Population Surveillance/methods , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Bacterial/analysis , Child , Child, Preschool , Cohort Studies , Denmark/epidemiology , Disease Notification , Enzyme-Linked Immunosorbent Assay , Female , Humans , Incidence , Infant , Infant, Newborn , Lyme Disease/epidemiology , Lyme Neuroborreliosis/epidemiology , Lyme Neuroborreliosis/microbiology , Male , Middle Aged , Polymerase Chain Reaction/methods , Young Adult
10.
Clin Microbiol Infect ; 21(4): 344.e13-21, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25658520

ABSTRACT

This national population-based study was conducted as part of the development of a national automated surveillance system for hospital-acquired bacteraemia and ascertains the utilization of blood cultures (BCs). A primary objective was to understand how local differences may affect interpretation of nationwide surveillance for bacteraemia. From the Danish Microbiology Database, we retrieved all BCs taken between 2010 and 2013 and linked these to admission data from the National Patient Registry. In total, 4 587 295 admissions were registered, and in 11%, at least one BC was taken. Almost 50% of BCs were taken at admission. The chance of having a BC taken declined over the next days but increased after 4 days of admission. Data linkage identified 876 290 days on which at least one BC was taken; 6.4% yielded positive results. Ten species, Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Enterococcus faecium, Enterococcus faecalis, Pseudomonas aeruginosa, Candida albicans, Enterobacter cloacae and Klebsiella oxytoca, accounted for 74.7% of agents for this purpose classified as pathogenic. An increase in BCs and positive BCs was observed over time, particularly among older patients. BCs showed a seasonal pattern overall and for S. pneumoniae particularly. A predominance of male patients was seen for bacteraemias due to S. aureus, E. faecium and K. pneumoniae. Minor differences in BCs and positive BCs between departments of clinical microbiology underpin the rationale of a future automated surveillance for bacteraemia. The study also provides important knowledge for interpretation of surveillance of invasive infections more generally.


Subject(s)
Bacteremia/diagnosis , Bacteria/isolation & purification , Bacteriological Techniques/methods , Blood/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Bacteremia/epidemiology , Bacteremia/microbiology , Bacteria/classification , Child , Child, Preschool , Denmark/epidemiology , Female , Hospitals , Humans , Infant , Infant, Newborn , Male , Middle Aged , Seasons , Sex Factors , Young Adult
12.
Eur J Clin Microbiol Infect Dis ; 34(4): 727-36, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25421216

ABSTRACT

The diagnosis of Clostridium difficile infection (CDI) requires the detection of toxigenic C. difficile or its toxins and a clinical assessment. We evaluated the performance of four nucleic acid amplification tests (NAATs) detecting toxigenic C. difficile directly from faeces compared to routine toxigenic culture. In total, 300 faecal samples from Danish hospitalised patients with diarrhoea were included consecutively. Culture was performed in duplicate (routine and 'expanded toxigenic culture': prolonged and/or re-culture) and genotypic toxin profiling by polymerase chain reaction (PCR), PCR ribotyping and toxinotyping (TT) were performed on culture-positive samples. In parallel, the samples were analysed by four NAATs; two targeting tcdA or tcdB (illumigene C. difficile and PCRFast C. difficile A/B) and two multi-target real-time (RT) PCR assays also targeting cdt and tcdC alleles characteristic of epidemic and potentially more virulent PCR ribotypes 027, 066 and 078 (GeneXpert C. difficile/Epi and an 'in-house RT PCR' two-step algorithm). The multi-target assays were significantly more sensitive compared to routine toxigenic culture (p < 0.05) and significantly more robust to inhibition compared to PCRFast (p < 0.001). Duplicate 'expanded toxigenic culture' increased the culture-positive rate by 29% compared to routine culture. The ability of the GeneXpert and in-house assays to correctly classify PCR ribotype 027 was high (>95%), and in-house PCR displayed 100% correct identification of PCR ribotypes 066 and 078. Furthermore, the presence of the PCR enhancer bovine serum albumin (BSA) was found to be related to high sensitivity and low inhibition rate. Rapid laboratory diagnosis of toxigenic C. difficile by RT PCR was accurate.


Subject(s)
Bacterial Toxins/analysis , Bacterial Toxins/genetics , Clostridioides difficile/isolation & purification , Clostridium Infections/diagnosis , Real-Time Polymerase Chain Reaction/methods , Adolescent , Adult , Aged , Aged, 80 and over , Cell Culture Techniques/methods , Child , Child, Preschool , Denmark , Feces/microbiology , Female , Humans , Infant , Male , Middle Aged , Molecular Diagnostic Techniques/methods , Sensitivity and Specificity , Young Adult
14.
Dement Geriatr Cogn Disord ; 33(2-3): 111-7, 2012.
Article in English | MEDLINE | ID: mdl-22508568

ABSTRACT

BACKGROUND: Early-onset Alzheimer's disease (EOAD) is generally thought to have a more rapid course compared to late-onset Alzheimer's disease (LOAD). The faster progression of EOAD observed in some studies has also been thought to correlate with cerebrospinal fluid (CSF) biomarkers. Our clinical experience has not been suggestive of any difference in disease progression; therefore, we decided to investigate whether differences in clinical progression and CSF biomarkers between EOAD and LOAD could be demonstrated. METHODS: Case-control study with 42 patients, 21 EOAD and 21 matched LOAD patients. Rates of progression were calculated and these, as well as CSF biomarker levels, were statistically compared. RESULTS: There were no statistically significant differences in clinical progression between the EOAD group and the LOAD group. There was no significant difference in the absolute values of CSF biomarkers, but a tendency towards lower levels of ß-amyloid in patients with EOAD was observed. CONCLUSIONS: Our findings did not converge with results from the majority of previous studies, which have been suggestive of a faster clinical progression in EOAD. Possibly, the very strict algorithm by which our patients were matched explains our findings. However, the findings should be repeated in a larger study population.


Subject(s)
Alzheimer Disease , Amyloid beta-Peptides/cerebrospinal fluid , Memory Disorders , Mental Competency , Age of Onset , Aged , Aged, 80 and over , Alzheimer Disease/diagnosis , Alzheimer Disease/epidemiology , Alzheimer Disease/metabolism , Alzheimer Disease/psychology , Biomarkers , Case-Control Studies , Denmark/epidemiology , Disease Progression , Early Diagnosis , Female , Geriatric Assessment/methods , Humans , Intelligence Tests , Male , Middle Aged , Prognosis , Psychiatric Status Rating Scales , Registries/statistics & numerical data
15.
Acta Neuropathol ; 101(6): 601-4, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11515789

ABSTRACT

Brain tissue from 25 patients with clinically definite multiple sclerosis (MS) and as controls brain tissue from 36 patients without neurological disease was tested for the presence of human coronaviral RNA. Four PCR assays with primers specific for N-protein of human coronavirus strain 229E and three PCR assays with primers specific for the nucleocapsid protein of human coronavirus strain OC43 were performed. Sporadic positive PCR assays were observed in both patients and controls in some of the PCR assays. However, these results were not reproducible and there was no difference in the proportion of positive signals from the MS patients compared to controls. Evidence for a chronic infection with the human coronaviruses strain 229E or OC43 in brain tissue from patients with MS or controls has not been found in this study.


Subject(s)
Brain/virology , Coronavirus/ultrastructure , Multiple Sclerosis/virology , Adult , Aged , Aged, 80 and over , Brain/pathology , DNA Primers , Female , Humans , Male , Middle Aged , Multiple Sclerosis/pathology , Myelin Basic Protein/genetics , RNA, Viral/analysis , Reverse Transcriptase Polymerase Chain Reaction
16.
J Antimicrob Chemother ; 46(6): 973-80, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11102417

ABSTRACT

The combination of beta-lactam antibiotics and macrolides is often recommended for the initial empirical treatment of acute pneumonia in order to obtain activity against the most important pathogens. Theoretically, this combination may be inexpedient, as the bacteriostatic agent may antagonize the effect of the bactericidal agent. In this study, the possible interaction between penicillin and erythromycin was investigated in vitro and in vivo against four clinical isolates of Streptococcus pneumoniae with MICs of penicillin ranging from 0.016 to 0.5 mg/L and of erythromycin from 0. 25 to >128 mg/L. In vitro time-kill curves were generated with clinically relevant concentrations of penicillin (10 mg/L) and erythromycin (1 mg/L), either individually or in combination. Antagonism between penicillin and erythromycin was observed for the four isolates. In vivo interaction was investigated in the mouse peritonitis model. After intraperitoneal inoculation, penicillin and erythromycin were given either individually or in combination. For two of the four isolates, mortality was significantly higher in the groups treated with the combination of penicillin and erythromycin than in the groups treated with penicillin alone [32/36 (86%) vs. 3/12 (25%), P<0.05; and 24/36 (67%) vs. 3/12 (25%), P<0.05, respectively]. Using the mouse peritonitis model, in vivo time-kill curves showed that there was antagonism between erythromycin and penicillin for the examined isolate. The antagonism demonstrated in vitro and in vivo between penicillin and erythromycin suggests that ss-lactam antibiotics and macrolides should not be administered together unless pneumococcal infection is ruled out.


Subject(s)
Erythromycin/pharmacology , Penicillins/pharmacology , Streptococcus pneumoniae/drug effects , Animals , Drug Resistance, Microbial , Erythromycin/antagonists & inhibitors , Female , Mice , Microbial Sensitivity Tests , Penicillins/antagonists & inhibitors , Pneumococcal Infections/drug therapy
17.
Acta Neurol Scand ; 100(2): 88-91, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10442448

ABSTRACT

UNLABELLED: Acute monosymptomatic optic neuritis (AMON) may be an initial symptom of multiple sclerosis (MS). Coronaviruses have been implicated in the etiology of MS. The objective of the present study was to look for coronaviral RNA in AMON, which could be present in the initial stages of the development of MS. MATERIAL AND METHODS: Spinal fluids from 37 patients with AMON and 15 surgical control patients with protrusion of the intervertebral disk were assayed with a nested multiplex polymerase chain reaction with primers specific for human coronaviruses strain (HCV) 229E and OC43. RESULTS: Four patients and 1 control were positive for HCV-229E. No evidence of HCV-OC43 was found. The frequency of positive samples was low and there was no statistical difference between AMON and controls. CONCLUSION: This study does not provide evidence for an etiological role of human coronaviruses in acute monosymptomatic optic neuritis.


Subject(s)
Cerebrospinal Fluid/virology , Coronavirus 229E, Human , Coronavirus Infections/diagnosis , Coronavirus OC43, Human , Coronavirus/isolation & purification , Optic Neuritis/diagnosis , Acute Disease , Adolescent , Adult , Coronavirus/genetics , Coronavirus Infections/virology , Female , Humans , Male , Middle Aged , Optic Neuritis/virology , RNA/genetics , RNA, Viral/cerebrospinal fluid , Reverse Transcriptase Polymerase Chain Reaction
18.
Acta Neurol Scand ; 95(5): 284-6, 1997 May.
Article in English | MEDLINE | ID: mdl-9188903

ABSTRACT

OBJECTIVES: Epidemiological evidence suggests that an infectious agent may be involved in the pathogenesis of multiple sclerosis (MS). Picornaviruses are possible candidates for an etiological agent, because of their neurotropic properties and ability to cause chronic infections. MATERIALS AND METHODS: Autopsy brain tissue from 25 patients with clinically definite MS and 33 control patients without inflammatory neurological disease was tested with reverse transcription PCR specific for enteroviruses and cardioviruses. RESULTS: All specimens were found negative. CONCLUSION: These results do not support the theory of a persisting entero- or cardioviral infection as the cause of Ms as we found no evidence of the presence of entero- or cardioviral genomes in the brains from MS patients.


Subject(s)
Brain/virology , Cardiovirus/isolation & purification , Enterovirus/isolation & purification , Multiple Sclerosis/virology , RNA, Viral , Adult , Aged , Brain/pathology , Female , Genome , Humans , Male , Middle Aged , Multiple Sclerosis/pathology , Polymerase Chain Reaction , RNA, Messenger , Transcription, Genetic
19.
Eur Respir J ; 8(4): 651-3, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7664868

ABSTRACT

A 53 year old male with symptoms of coughing for 6 months presented with bilateral multiple pulmonary nodules suggestive of metastatic disease. By surgical resection 4 out of 6 nodules were removed. Histopathological examination showed granulomatous necrotizing inflammation with growth of Corynebacterium ulcerans, which did not produce diphtheria toxin. The patient was treated with penicillin for 1 week. Follow-up for 2 yrs showed no sign of recurrence.


Subject(s)
Corynebacterium Infections , Granuloma/microbiology , Lung Diseases/microbiology , Corynebacterium Infections/diagnostic imaging , Corynebacterium Infections/pathology , Corynebacterium Infections/surgery , Granuloma/diagnostic imaging , Granuloma/pathology , Granuloma/surgery , Humans , Lung/pathology , Lung Diseases/diagnostic imaging , Lung Diseases/pathology , Lung Diseases/surgery , Male , Middle Aged , Radiography
20.
SELECTION OF CITATIONS
SEARCH DETAIL
...